Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
The advent of molecular medicine has transformed breast cancer management. Breast cancer is now recognised as a heterogenous disease with varied morphology, molecular features, tumour behaviour, and response to therapeutic strategies. These parameters are underpinned by a combination of genomic and...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/17/4455 |
| _version_ | 1797521597326688256 |
|---|---|
| author | Matthew G. Davey Sean O. Hynes Michael J. Kerin Nicola Miller Aoife J. Lowery |
| author_facet | Matthew G. Davey Sean O. Hynes Michael J. Kerin Nicola Miller Aoife J. Lowery |
| author_sort | Matthew G. Davey |
| collection | DOAJ |
| description | The advent of molecular medicine has transformed breast cancer management. Breast cancer is now recognised as a heterogenous disease with varied morphology, molecular features, tumour behaviour, and response to therapeutic strategies. These parameters are underpinned by a combination of genomic and immunohistochemical tumour factors, with estrogen receptor (ER) status, progesterone receptor (PgR) status, human epidermal growth factor receptor-2 (HER2) status, Ki-67 proliferation indices, and multigene panels all playing a contributive role in the substratification, prognostication and personalization of treatment modalities for each case. The expression of Ki-67 is strongly linked to tumour cell proliferation and growth and is routinely evaluated as a proliferation marker. This review will discuss the clinical utility, current pitfalls, and promising strategies to augment Ki-67 proliferation indices in future breast oncology. |
| first_indexed | 2024-03-10T08:14:46Z |
| format | Article |
| id | doaj.art-96ac88efb8884703ba9f22d67bbb5271 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T08:14:46Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-96ac88efb8884703ba9f22d67bbb52712023-11-22T10:27:41ZengMDPI AGCancers2072-66942021-09-011317445510.3390/cancers13174455Ki-67 as a Prognostic Biomarker in Invasive Breast CancerMatthew G. Davey0Sean O. Hynes1Michael J. Kerin2Nicola Miller3Aoife J. Lowery4Discipline of Surgery, The Lambe Institute for Translational Research, National University of Ireland, H91 YR71 Galway, IrelandDepartment of Histopathology, National University of Ireland, H91 YR71 Galway, IrelandDiscipline of Surgery, The Lambe Institute for Translational Research, National University of Ireland, H91 YR71 Galway, IrelandDiscipline of Surgery, The Lambe Institute for Translational Research, National University of Ireland, H91 YR71 Galway, IrelandDiscipline of Surgery, The Lambe Institute for Translational Research, National University of Ireland, H91 YR71 Galway, IrelandThe advent of molecular medicine has transformed breast cancer management. Breast cancer is now recognised as a heterogenous disease with varied morphology, molecular features, tumour behaviour, and response to therapeutic strategies. These parameters are underpinned by a combination of genomic and immunohistochemical tumour factors, with estrogen receptor (ER) status, progesterone receptor (PgR) status, human epidermal growth factor receptor-2 (HER2) status, Ki-67 proliferation indices, and multigene panels all playing a contributive role in the substratification, prognostication and personalization of treatment modalities for each case. The expression of Ki-67 is strongly linked to tumour cell proliferation and growth and is routinely evaluated as a proliferation marker. This review will discuss the clinical utility, current pitfalls, and promising strategies to augment Ki-67 proliferation indices in future breast oncology.https://www.mdpi.com/2072-6694/13/17/4455breast cancerbiomarkerKi-67MIB-1personalised medicine |
| spellingShingle | Matthew G. Davey Sean O. Hynes Michael J. Kerin Nicola Miller Aoife J. Lowery Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer Cancers breast cancer biomarker Ki-67 MIB-1 personalised medicine |
| title | Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer |
| title_full | Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer |
| title_fullStr | Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer |
| title_full_unstemmed | Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer |
| title_short | Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer |
| title_sort | ki 67 as a prognostic biomarker in invasive breast cancer |
| topic | breast cancer biomarker Ki-67 MIB-1 personalised medicine |
| url | https://www.mdpi.com/2072-6694/13/17/4455 |
| work_keys_str_mv | AT matthewgdavey ki67asaprognosticbiomarkerininvasivebreastcancer AT seanohynes ki67asaprognosticbiomarkerininvasivebreastcancer AT michaeljkerin ki67asaprognosticbiomarkerininvasivebreastcancer AT nicolamiller ki67asaprognosticbiomarkerininvasivebreastcancer AT aoifejlowery ki67asaprognosticbiomarkerininvasivebreastcancer |